Hyperinsulinism of infancy: Towards an understanding of unregulated insulin release

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 82, Issue 2, 2000, Pages

  Shepherd, Ruth M ^a   Cosgrove, Karen E ^a   O'Brien, Rachel E ^a   Barnes, Philippa D ^a   Ämmälä, Carina ^a   Dunne, Mark J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

ATP sensitive potassium channels; Diazoxide; Hyperinsulinism; Hypoglycaemia; Insulin secretion; Nesidioblastosis

Indexed keywords

CALCIUM ION; DIAZOXIDE; INSULIN; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM SIGNALING; GENE MUTATION; GENE THERAPY; HUMAN; HYPERINSULINISM; HYPOGLYCEMIA; INFANT; INSULIN RELEASE; INSULINOMA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0034064505     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.82.2.f87     Document Type: Article

References (81)

1. 1 Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic β-cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329 39.
2. 2 Leibiger B, Moede T, Schwarz T, et al. Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci U S A 1998;95:9307-12.
3. 3 Aspinwall CA, Lakey JR, Kennedy RT. Insulin-stimulated insulin secretion in single pancreatic β-cells. J Biol Chem 1999;274:6360-5.
4. 4 Dunne MJ, Petersen OH. Potassium selective ion channels in insulin-secreting cells; physiology, pharmacology and their role in stimulus secretion coupling. Biochim Biophys Acta 1991;1071:67-82.
5. 5 Wollheim CB, Sharp GWG. Regulation of insulin release by calcium. Physiol Rev 1981;61:914-73.
6. 1 oscillations in transgenically derived β-cells. J Biol Chem 1998;273:10402-10.
7. 2+-sensitive non-selective cation channels in regulating the membrane potential of pancreatic β-cells. Diabetes 1998;47:1066-73.
8. 8 J Lang. Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999;259:3-17.
9. 9 Aizawa T, Komatsu M, Asanuma N, Sato Y, Sharp GWG. Glucose action "beyond ionic events" in the pancreatic β-cell. Trends Pharmacol Sci 1998;19:496-9.
10. 10 Komatsu M, Aizawa T, Yokokawa N, Sato Y, Takasu N, Yamada T. Mastoparan-induced hormone release from rat pancreatic islets. Endocrinology 1992;30:221-8.
11. + channels in mouse B cells. J Clin Invest 1992;89:1288-95.
12. +) permeability. Biochem Pharmacol 1992;43:2483-5.
13. ATP channel-independent signalling pathways in human islets. Diabetes 1998;47:758-64.
14. 14 Straub SG, James RFL, Dunne MJ, Sharp GWG. Glucose augmentation of mastoparan-stimulated insulin secretion in rat and human pancreatic islets. Diabetes 1998;47:1053-7.
15. + channel-independent pathway of glucose signalling in rat pancreatic islets. Diabetes 1999;48:1006-12.
16. 16 Melloul D, Ben-Neriah Y, Cerasi E. Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters. Proc Natl Acad Sci U S A 1993;90:3865-9.
17. 17 Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994;371:606-9.
18. 18 Macfarlane WM, Cragg H, Docherty HM, et al. Impaired expression of transcription factor IUF1 in a cell line derived from a patient with persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis). FEBS Lett 1997;413:304-8.
19. + channels. Trends Neurosci 1998;21:288-94.
20. ATP channels. Physiol Rev 1998;78:227-45.
21. 21 Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the β-cell high-affinity sulphonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-6.
22. ATP an inward rectifier subunit plus the sulphonylurea receptor. Science 1995;270:1166-70.
23. 23 Tusnady GE, Bakos E, Varadi A, Sarkadi B. Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters. FEBS Lett 1997;402:1-3.
24. + channels. Neuron 1995;16:1011-17.
25. 25 Sakura H, Ämmälä C, Smith PA, Gribble FM, Ashcroft FM. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel expressed in pancreatic β-cells, brain, heart and skeletal muscle. FEBS Lett 1995;377:338-44.
26. ATP channel subunits. Neuron 1997;18:827-38.
27. ATP channel complex. J Gen Physiol 1997;110:655-64.
28. + channels. Endocr Rev 1999;20:101-35.
29. ATP channels. J Biol Chem 1999;274:20628-32.
30. ATP channels. Neuron 1999;22:537-48.
31. ATP channel: separate role of Kir6.2 and SUR1 subunit phosphorylation. EMBO J 1999;18:4722-32.
32. ATP channel. Diabetes 1999;48:1341-7.
33. 33 Uhde I, Toman A, Gross I, Schwanstecher C, Schwanstecher M. Identification of the potassium channel opener site on sulfonylurea receptors. J Biol Chem 1999;274:28079-82.
34. 34 Dorschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol 1999;55:1060-6.
35. 35 Ashcroft FM, Ashcroft SJH. The sulphonylurea receptor. Biochim Biophys Acta 1992;1175:45-59.
36. ATP channels. Diabetes 1999;45:1439-45.
37. ATP channels is mediated by Kir 6.2. Proc Natl Acad Science U S A 1998;94:11716-20.
38. 38 Lawson K. Potassium channel activation: a potential therapeutic approach? Pharmacol Ther 1996;70:39-63.
39. + channels and inhibition of insulin release; effect of BPDZ-62. J Pharmacol Exp Ther 1996;277;156-62.
40. 40 Dunne MJ. Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol 1990;99:487-92.
41. 41 Nestorowicz A, Glaser B, Wilson BA, et al. Genetic heterogeneity in familial hyperinsulinism. Hum Mol Genet 1998;7:1119-28.
42. 42 Otonkoski T, Ämmälä C, Huopio H, et al. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycaemia of infancy in Finland. Diabetes 1999;48:408-15.
43. 43 Thomas PM, Wohllk N, Huang E, et al. Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. Am J Hum Genet 1996;59:510-18.
44. 44 Kentrup H, Altmüller J, Karhausen S, Hauffa B, Pfäffle R. Novel mutation of the sulfonylurea receptor-1 (SUR1) gene in persistent hyperinsulinemic hypoglycaemia of infancy (PHHI). Horm Res 1999;55:45.
45. 45 Nestorowicz A, Wilson BA, Schoor KP, et al. Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet 1996;5:1813-22.
46. 46 Verkarre V, Fournet JC, de Lonlay P, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286-91.
47. 47 De Lonlay-Debeney P, Poggi-Travert F, Fournet JC, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999;340:1169-75.
48. 48 Dunne MJ, Kane C, Shepherd RM, et al. Familial persistent hyperinsulinaemic hypoglycaemia of infancy and mutations in the sulphonylurea receptor. N Engl J Med 1997;336:703-6.
49. 49 Meissner T, Brune W, Mayatepek E. Persistent hyperinsulinaemic hypoglycemia of infancy: therapy, clinical outcome and mutational analysis. Eur J Pediatr 1997;156:754-7.
50. 50 Nestorowicz A, Inagaki N, Gonoi T, et al. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes 1997;46:1743-8.
51. 51 Hupio H, Komulainen J, Rissanen J, Lenko H-L, Laakso M, Otonkoski T. A novel point mutation in sulfonylurea receptor 1 gene associates to diazoxide-responsive form of congenital hyperinsulinism. Horm Res 1997;55:15P.
52. 52 Thomas PM, Cote GJ, Wohllk N, et al. Mutations of the sulphonylurea receptor gene in familial persistent hyperinsulinemic hypoglycaemia of infancy. Science 1995;268:426-9.
53. 53 Glaser B, Landau H, Permutt MA. Neonatal hyperinsulinism. Trends Endocrinol Metab 1999;10:55-61.
54. 54 Aynsley-Green A, Polak JM, Bloom SR, et al. Nesidioblastosis of the pancreas: definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycaemia. Arch Dis Child 1981;56:496-508.
55. 55 Kane C, Lindley KJ, Johnson PRV, et al. Therapy for persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI); understanding the responsiveness of β-cells to diazoxide and somatostatin. J Clin Invest 1997;100:1888-93.
56. ATP channels in pancreatic β-cells causes persistent hyperinsulinaemic hypoglycaemia of infancy. Nat Med 1996;2:1344-7.
57. 57 Dunne MJ, Cosgrove KE, Shepherd RM, Ämmälä C. Potassium channels, sulphonylurea receptors and control of insulin release. Trends Endocrinol Metab 1999;10:146-53.
58. 58 Shyng SL, Ferrigni T, Shepard JB, et al. Functional analyses of novel mutations in the sulphonylurea receptor 1 associated with persistent hyperinsulinaemic hypoglycaemia of infancy. Diabetes 1998;47:1145-51.
59. 59 Ryan F, Devaney D, Joyce C, et al. Hyperinsulinism: molecular aetiology of focal disease. Arch Dis Child 1998;79:445-7
60. 60 Lindley KJ, Dunne MJ, Kane C, et al. Ionic control of β-cell function in nesidioblastosis. A possible therapeutic role for calcium channel blockade? Arch Dis Child 1996;74:373-8.
61. + conductance in glucose-stimulated pancreatic β-cells. Nature 1991;353:849-52.
62. 62 Eichmann D, Hufnagel M, Quick P, Santer R. Treatment of hyperinsulinaemic hypoglycaemia with nifedipine. Eur J Pediatr 1999;158:204-6
63. 63 Cosgrove KE, Shepherd RM, Hashmi MN, et al. The role of calcium ions in determining insulin hypersecretion in patients with persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI). Horm Res 1999;55:15P.
64. + channels in mouse pancreatic β-cells. J Physiol 1990;423:311-25.
65. 65 Rorsman P, Trube G. Calcium and delayed potassium currents in mouse β-cells under voltage-clamp conditions. J Physiol 1986;371:531-50.
66. + channels and their significance for action potential repolarization in mouse pancreatic β-cells. J Gen Physiol 1990;95:1041-59.
67. 67 Kalman K, Nguyen A, Tseng-Crank J, et al. Genomic organisation, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. J Biol Chem 1998;273:5851-7.
68. + channels. Role in stimulus-secretion coupling. J Biol Chem 1996;271:32241-6.
69. ATP channel function. J Physiol 1998;509:189P.
70. ATP channel. Proc Natl Acad Science U S A 1997;94:11969-73.
71. 71 Patel YC, Srikant CB. Somatostatin receptors. Trends Endocrinol Metab 1997;8:398-405.
72. ATP deficient mice. Proc Natl Acad Sci U S A 1998;95:10402-6.
73. + channel in insulin-secreting pancreatic β-cells. J Mol Endocrinol 1999:22 113-23.
74. ATP channel deficient SUR1-mice. Diabetes 1999;48(suppl 1):A34.
75. 75 Glaser B, Kesavan P, Heyman M, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226-30.
76. 76 Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998;338:1352-7.
77. 77 Service FJ, Natt N, Thompson GB, et al. Non-insulinoma pancreatogenous hypoglycaemia: a novel syndrome of hyperinsulinemic hypoglycaemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999;84:1582-9.
78. 78 Froguel P, Velho G. Molecular genetics of maturity-onset diabetes of the young. Trends Endocrinol Metab 1999;10:142-6.
79. 79 Yorifuji T, Muroi J, Uematsu A, Hiramatsu H, Momoi T. Hyperinsulinism-hyperammonerma syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics. Hum Genet 1999;104:476-9
80. 80 MacFarlane WM, Chapman JC, Shepherd RM, et al. Engineering a glucose-responsive human insulin-secreting cell line from islets of Langerhans isolated from a patient with persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI). J Biol Chem 1999;274:34059-66.
81. 81 Aynsley-Green A, Dunne MJ, James, Lindley KJ. Ions and genes in persistent hyperinsulinaemic hypoglycaemia of infancy; a commentary on the implications for tailoring treatment to disease pathogenesis. J Pediatr Endocrinol 1998;11:121-9.